New Issue: Science’s Impossible Questions. Read Now

Magnetic Levitation Lifts Impurities from Pharmaceuticals

Separating therapeutic molecules from nonhelpful "twins" is tough, but a new magnetic method that can pull them apart may be the answer

Join Our Community of Science Lovers!

A team in the US has shown that enantiopure and racemic crystals can be separated by magnetic levitation.

The isolation of pure enantiomers is of particular importance in the pharmaceutical industry, where one enantiomer is typically responsible for the therapeutic effects of a drug, while the other may be inactive or even toxic. One alternative to the often used solution-based separation techniques such as high-performance liquid chromatography (HPLC) is to purify the desired enantiomer from a mixture of crystals of enantiomerically pure and racemic compound.

As enantiopure and racemic crystals generally have different densities due to distinct packing arrangements of the molecules, they can be levitated in a paramagnetic solution to different heights by the balance of magnetic and gravitational forces and then separated.


On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.


Using four sequential magnetic levitation (MagLev) separations, a team led by Allan Myerson at the Massachusetts Institute of Technology purified a 1:1 mixture of S- and RS-ibuprofen to 99.2% ee.

‘Chiral resolution, especially during drug discovery, requires tedious method development by an experienced scientist to achieve efficient separation,’ says Syed Rizvi, a chiral separations and pharmaceutical analysis expert at Nova Southeastern University in the US. ‘The MagLev technique however is quite simple, inexpensive and has great potential to become a routine method for chiral separation.’

Despite its simplicity, the use of MagLev on a large scale presents a number of challenges. ‘As it requires that the racemic crystal forms reliably, does not stick to enantiomerically pure crystals, and has a different density, it is more likely to be used in an analytical laboratory setting engaged in preclinical studies of a compound,’ says Myerson. The need for an equilibration time for the drug crystals to settle as well as the choice of paramagnetic medium also need to be considered.

The team are currently working to apply MagLev to the purification of other chiral compounds, and hope to extend their technique to the separation of cocrystals.

This article is reproduced with permission from Chemistry World. The article was first published on June 18, 2014.

Subscribe to Support Independent Journalism

Great science journalism requires human expertise, time, effort and creativity. And it costs money. That’s why I and the journalists here at Scientific American hope you’ll join our community.

When you subscribe, you are supporting staff and freelance journalists who are passionate about telling science stories that are true, important and compelling. Our editors and reporters are often experts in their fields, which means they understand the nuances of big discoveries and can untangle the breakthroughs from the hype. With a subscription, you are also supporting rigorous fact-checking to ensure the words we publish are precise and accurate. And you’re supporting original illustrations, graphics and photos that bring you closer to an advanced laboratory, an ice sheet in Antarctica or a space mission in orbit. You’re helping us craft other types of high-quality journalism as well: Our newsletters are carefully written, edited and curated by staffers you have or will come to know and love. Our Science Quickly podcast is based on original reporting, collaboration with editors and scientists and exacting production.

Subscriptions keep this engine running so we can continue to deliver thoughtful, rigorous and independent science journalism to you. In an era of viral misinformation, this work is crucial. If you value what we do, I hope you’ll consider joining us as a subscriber

Thank you,

Jeanna Bryner, Editor in Chief, Scientific American

Subscribe